CA
NZ
UK
AU
IND
US
● An NYSE minimum-price compliance deadline looms this fall, adding listing pressure to the stock.
● Surf Air Mobility reported second-quarter 2026Revenueof $29.5 million on August 10, at the high end of its guided $27 million to $30 million range.
● Quantum-Si Incorporated reported second-quarter 2026 results on August 13 that beat thinWall StreetRevenueestimates.
● Skye Bioscience discontinued its Phase 2a CBeyond trial of nimacimab in obesity on August 14, 2026.
● Outlook Therapeutics won FDA approval for LYTENAVA (bevacizumab-vikg) on July 24, 2026, the first and only FDA-approved ophthalmic formulation of bevacizumab.
● Nerdy, Inc. shares closed around $0.71 on August 14, 2026, near the low end of a 52-week range of $0.70 to $1.49.
● OSR Health faces an August 31, 2026 deadline to maintain a $1.00 closing bid price for 10 consecutiveBusinessdays underNasdaqrules.
● WM Technology clawed back some ground from its 52-week low of roughly $0.31, trading near $0.40 in mid-August 2026.
● Mereo BioPharma Group's American Depositary Shares climbed sharply following its August 11, 2026 second-quarterEarningsrelease.
● Lead candidate laromestrocel, formerly known as Lomecel-B, is an allogeneic, bone-marrow-derived mesenchymal stem cell product being tested in two very different populations.
Please wait processing your request...